MedTrace Logo

Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

NCT05817201 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-04-18

No results posted yet for this study

Summary

The goal of this clinical trial is to explore the therapeutic efficacy of immune checkpoint inhibitors combined with radical radiotherapy in elderly patients with esophageal cancer.

Conditions

  • Esophageal Cancer
  • Radiation Therapy
  • Immunotherapy
  • Chemotherapy

Interventions

DRUG

Toripalimab

Toripalimab 240mg day7 and day 28，every 3 weeks 1month after radiotherapy，until progression or 1 years or intolerant.

DRUG

Tegafur

Tegafur 70mg/m2/day day 1 to day 14，and day 29 to day42.

RADIATION

IMRT

PGTV 54Gy/2.16Gy/25F/5W, PTV 45Gy/1.8Gy/25F/5W

Sponsors & Collaborators

  • Taizhou Hospital

    lead OTHER

Principal Investigators

  • Taizhou Enze Medical Center(Group) Enze Hospital Yang, MD · Taizhou Enze Medical Center Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05817201 on ClinicalTrials.gov